Vaccinex Inc

Vaccinex, Inc. operates as a clinical-stage biotechnology company. It engages in the development of targeted bio therapeutics to treat serious diseases and conditions with unmet medical needs, including cancer, neurodegenerative diseases, and autoimmune disorders. The firm focuses on the development of Pepinemab for the treatment of non-small cell lung cancer, or NSCLC, osteosarcoma, melanoma, and Huntington’s disease. Its product pipeline includes the SEMA4D antibody platform and ActivMAb antibody discovery platform. The company was founded by Maurice Zauderer and Deepak Sahasrabudhe in 1997 and is headquartered in Rochester, NY.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Vaccinex, Inc. operates as a clinical-stage biotechnology company. It engages in the development of targeted bio therapeutics to treat serious diseases and conditions with unmet medical needs, including cancer, neurodegenerative diseases, and autoimmune disorders. The firm focuses on the development of Pepinemab for the treatment of non-small cell lung cancer, or NSCLC, osteosarcoma, melanoma, and Huntington’s disease. Its product pipeline includes the SEMA4D antibody platform and ActivMAb antibody discovery platform. The company was founded by Maurice Zauderer in April 2001 and is headquartered in Rochester, NY.

Evolus

Novavax

Novavax (NASDAQ: NVAX) shares are trading higher Friday after the company announced a Memorandum of Understanding with Gavi to provide 1.1 billion cumulative doses of NVX-CoV2373. Novavax is a biotechnology company that develops vaccines.

Why Novavax, Vaccinex, Evolus Are Trading Higher Today

Vaccinex stock rocketed up more than 200% Friday, propelled by two collaboration deals centered on using the biotech company's antibody discovery platform.  Vaccinex, which focuses on cancer and neurodegenerative disease, said it signed multi-project deals with two unnamed "prominent" pharmaceutical companies. Financial terms of the deals were undisclosed.

Vaccinex stock soars 223% on partnership deals using its antibody discovery platform (VCNX)

Shares of Vaccinex Inc. soared toward a record rally on record volume Friday, after the biotechnology company announced the signing of multiple-project deals with two "prominent" pharmaceutical companies. The collaborations will focus on the use of Vaccinex's antibody discovery and novel viral display platform, ActivMAb, for antibody discovery.

Vaccinex's stock soars toward record gain on record volume after deals with 'prominent' drug makers

Vaccinex (VCNX) stock is rocketing higher on Friday after following an announcement about multi-project deals with two comapnies. The post VCNX Stock: 11 Things to Know About Vaccinex and the Deals That Have Shares Soaring appeared first on InvestorPlace.

VCNX Stock: 11 Things to Know About Vaccinex and the Deals That Have Shares Soaring

Shares of micro-cap biopharma Vaccinex Inc (NASDAQ: VCNX) were trading higher Friday on above-average volume. Rochester, New York-based Vaccinex, which focuses on therapies for cancer and neurodegenerative diseases, announced the signing of multiproject deals with two prominent pharma companies that Vaccinex did not identify.

Why Vaccinex Shares Are Rallying

The stock price of Vaccinex Inc (Nasdaq: VCNX) is trading at over 60% pre-market. This is why it happened.

VCNX Stock Price Increases Over 60% Pre-Market: Why It Happened

Vaccinex Inc (NASDAQ: VCNX) jumps premarket in reaction to multi-project deals signed with two undisclosed prominent pharmaceutical companies, utilizing Vaccinex's ActivMAb, antibody discovery, and novel viral display platform for antibody discovery against complex antigens such as GPCRs and ion channels. The financial terms of the deals were not disclosed.

Vaccinex Rallies After Announcing Multi-Project Pact Using Its Antibody Discovery Platform

Partnerships will use Vaccinex's ActivMAb® platform for viral display of complex antigens to enable antibody discovery Partnerships will use Vaccinex's ActivMAb® platform for viral display of complex antigens to enable antibody discovery

Vaccinex Announces Signing of Two Multi-Project Deals with Leading Pharmaceutical Companies Focused on Leveraging Its ActivMAb® Platform

BJ`s Wholesale Club Holdings Inc

Bellicum Pharmaceuticals

Liminal BioSciences

360 Finance Inc - ADR

Meridian Bioscience

Want to try some out-of-the-box approach? Tap five stocks with increasing P/E ratios.

Bet on Rising P/E With These 5 Top-Ranked Stocks

ROCHESTER, N.Y., Jan. 05, 2021 (GLOBE NEWSWIRE) -- Vaccinex, Inc. (Nasdaq: VCNX), a clinical-stage biotechnology company pioneering a differentiated approach to treating cancer and neurodegenerative disease through the inhibition of SEMA4D, today announced that it will participate in the 10th Annual LifeSci Partners Corporate Access Event, January 6-8 and 11-14, 2021.

Vaccinex to Participate in the LifeSci Partners 10th Annual Healthcare Corporate Access Event

Addition al data from SIGNAL Huntington's disease (HD) trial support continued development in H D and in Alzheimer's disease (AD)

Vaccinex Reports Third Quarter 2020 Financial Results and Provides Corporate Update

SIGNAL Phase 2 trial data continue to support cognitive benefit and reduced brain atrophy with pepinemab treatment in Huntington's disease

CORRECTION -- Vaccinex to Present Additional SIGNAL Data at Huntington Study Group 2020 Medical Conference

Vaccinex to Present Additional SIGNAL Data at Huntington Study Group 2020 Medical Conference

Live moderated video webcast discussion between members of management and Key Opinion Leader, Eric Siemers, MD on Tuesday, October 27th at 10:00 a.m. EDT Live moderated video webcast discussion between members of management and Key Opinion Leader, Eric Siemers, MD on Tuesday, October 27th at 10:00 a.m. EDT

Vaccinex, Inc. to Present at the Virtual Investor KOL Roundtable

Investors need to pay close attention to Vaccinex (VCNX) stock based on the movements in the options market lately.

Implied Volatility Surging for Vaccinex (VCNX) Stock Options

Shares of micro-cap immunotherapy company Vaccinex Inc (NASDAQ: VCNX) were plunging Tuesday in reaction to an adverse readout.

Vaccinex Plummets After Lead Drug Flunks Midstage Huntingon's Disease Study

Shares of Vaccinex Inc.  tumbled 61.6% in premarket trading on Tuesday after the preclinical biotechnology company said an experimental Huntington's disease treatment, pepinemab, did not meet the primary endpoints in a Phase 2 double-blind, placebo-controlled clinical trial. Earlier this month, Vaccinex had announced plans to study pepinemab in combination with Merck & Co.

Vaccinex's stock falls after investigational drug fails Huntington's disease study

K ey  cognitive endpoint s trending towards but did not reach  statistical  significance in early manifest population . O verall  study does not meet  pre-specified  co- primary endpoints

Top-Line Results of Phase 2 SIGNAL Study in Huntington’s Disease Support Potential for Cognitive Benefit of Pepinemab

ROCHESTER, N.Y., Sept.  17, 2020  (GLOBE NEWSWIRE) -- Vaccinex, Inc. (Nasdaq: VCNX), a clinical-stage biotechnology company pioneering a novel approach to treating cancer and neurodegenerative disease through the inhibition of SEMA4D, today announced that it has entered into a clinical collaboration agreement with Merck (known as MSD outside the US and Canada), through a subsidiary, to evaluate the combination of Vaccinex’s investigational SEMA4D inhibitor, pepinemab, and Merck’s anti-PD-1 therapy, KEYTRUDA® (pembrolizumab), in the treatment of patients with advanced, recurrent or metastatic head and neck squamous cell carcinoma (HNSCC).

Vaccinex Announces Clinical Collaboration with Merck to Evaluate Pepinemab in Combination with KEYTRUDA® in Advanced, Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma

ROCHESTER, N.Y., Aug.  27, 2020  (GLOBE NEWSWIRE) -- Vaccinex, Inc. (Nasdaq: VCNX), a clinical-stage biotechnology company pioneering novel investigational antibody therapies in Huntington’s disease (HD) and cancer, announced the appointment of Robert Scala as Chief Commercial Officer. Robert will build and lead all commercial functions at Vaccinex and provide strategic and functional oversight of commercial operations for the Company starting with pepinemab, potentially the first disease modifying treatment for Huntington’s disease. He will report to Maurice Zauderer, Ph.D., President and CEO, and serve as a member of the Company’s Executive Team.

Vaccinex Announces Appointment of Robert Scala as Chief Commercial Officer

Vaccinex, Inc. (VCNX) delivered earnings and revenue surprises of 23.53% and -100.00%, respectively, for the quarter ended June 2020.

Vaccinex, Inc. (VCNX) Reports Q2 Loss, Misses Revenue Estimates

On track to report potentially pivotal Phase 2 Huntington’s disease topline data by early October

Vaccinex Reports Second Quarter 2020 Financial Results and Provides Corporate Update

Vaccinex, Inc. (VCNX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report.

Vaccinex, Inc. (VCNX) May Report Negative Earnings: Know the Trend Ahead of Q2 Release

Avinger

Bioline RX

Proteostasis Therapeutics

Viveve Medical

Inside the top-ranked stocks that have been exhibiting rising price-to-earnings ratios.

Bet on Rising Price-to-Earnings With 5 Top Stocks

Vaccinex (VCNX) saw a big move last session, as its shares jumped more than 8% on the day, amid huge volumes.

News for Vaccinex Inc Stock (VCNX)